The core sequence is identical (MEHFPGP), but N-Acetyl Semax has one terminal modification: acetylation of the N-terminal α-amino group (Ac-MEHFPGP). Native Semax has a free N-end, which is quickly cleaved by aminopeptidases – hence its half-life measured in minutes. Acetylation blocks this point of attack, which in research models increases proteolytic stability and additionally increases the lipophilicity of the molecule. The pharmacophore core remains the same, so the mechanistic profile is likely similar to Semax, although it requires separate validation for the modified molecule. An unmodified version is available as a lyophilisate vial and as a spray for direct comparison.
N-Acetyl Semax 50 mg
N-Acetyl Semax 50 mg is an acetylated analogue of Semax (Ac-MEHFPGP) – an ACTH(4-7) fragment extended with Pro-Gly-Pro, with the N-terminus blocked by acetyl, in the form of a lyophilisate in a vial for reconstitution with bacteriostatic water. The same compound as the spray version, in a format that gives you the freedom to choose working concentrations and longer shelf life.
N-Acetyl Semax 50 mg - acetylated Semax analogue, research reagent in a vial
- N-Acetyl Semax: acetylated analogue of Semax (Ac-MEHFPGP).
- Vial of lyophilisate with a nominal content of 50 mg.
- Research Use Only reagent, not for use in humans or animals.
Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.
Native Semax disappears from the bloodstream within minutes – the half-life of the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro is measured in minutes, not hours. This is a known feature of short regulatory peptides: the pharmacophore core is active, but the free α-amino group of the N-terminus becomes the target of aminopeptidases before the molecule can act. N-Acetyl Semax is the peptide chemistry’s response to this limitation – the same core sequence as Semax, with one modification: acetylation of the N-terminal α-amino group (Ac-MEHFPGP).
Blocking the N-end hinders the attack of aminopeptidases, which in research models translates into greater proteolytic stability and higher lipophilicity of the molecule. N-Acetyl Semax is supplied as lyophilisate in a 50 mg vial — powder form, which the researcher reconstitutes himself with bacteriostatic water according to the parameters of the planned experiment. It’s the same compound as N-acetyl Semax spray for the nose, delivered in a different format: instead of a ready-made solution in an applicator, you receive a vial of lyophilisate, which remains stable for months in the freezer and allows you to select any working concentration.
The vial format is a standard starting point in preclinical protocols for neuroprotective peptides – it gives full control over the concentration and volume of the solution. In terms of its pharmacological profile, N-Acetyl Semax inherits the mechanisms of Semax: induction of BDNF and NGF expression in the hippocampus and cortex, central melanocortin profile of the ACTH(4-7) fragment analogue devoid of corticotropic activity, modulation of dopaminergic and serotonergic transmission, inhibition of enkephalinases and neuroprotection in cerebral ischemia models.
This is one of the better characterized representatives of the group peptides on brain function tested for cognitive functions. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.
REGULATORY STATUS
N-Acetyl Semax is not registered as a medicine in the EU or USA. Native Semax is registered as a medicinal product in the Russian Federation (not in the EU or the USA) – as a nootropic and neuroprotectant in the form of nasal drops, for indications including ischemic stroke, encephalopathy and optic neuropathy. The acetylated analogue has no registration as a medicine in the EU, the USA or Russia (EMA, Drugs@FDA, GRLS). Communicating the product as an “over-the-counter nootropic”, “memory peptide” or “neuroprotector for biohackers” is contrary to the Research Use Only framework.
Semax, ACTH fragment and the Russian school of neuroprotective peptides
To understand N-Acetyl Semax, you need to go back to the adrenocorticotropic hormone. ACTH is a 39-amino-acid pituitary peptide that stimulates the adrenal cortex to secrete cortisol – its classic hormonal function in the periphery. Already in the 1960s and 1970s, research showed that short fragments of the ACTH molecule, deprived of the part responsible for corticotropic activity, retain a clear effect on the central nervous system – on learning, memory and resistance to stress.
This opened up a separate direction: designing synthetic ACTH fragments as neuropeptides acting in the brain without an adrenal effect. In the 1980s, Ivan Ashmarin’s team at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow took a fragment of ACTH(4-7) — the Met-Glu-His-Phe sequence — and added the C-terminal tripeptide Pro-Gly-Pro to it.
The heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro was created, called Semax. The addition of proline tripeptide solved a specific problem: it protected the core from rapid degradation and at the same time enhanced the nootropic and neuroprotective profile in behavioral models. Semax was used in research on acute cerebral ischemia and cognitive disorders, and in the Russian Federation it was registered as a drug in the form of nasal drops – first as a nootropic, later in higher concentrations as a neuroprotector in ischemic stroke.
However, Semax remains a short-lived peptide in serum. N-Acetyl Semax is another step in the same design strategy: a stabilized modification in which the N-terminal α-amino group has been capped with acetyl (capping). This is a standard method of regulatory peptide chemistry – extending shelf life and increasing lipophilicity without changing the core responsible for activity.
Acetylation of the N-end removes the point of attack of aminopeptidases and changes the physicochemical profile of the molecule, which makes the acetylated analogue a separate subject of research characterization compared to native Semax.
What is N-Acetyl Semax?
N-Acetyl Semax is a synthetic heptapeptide – an N-acetylated derivative of Semax, an analogue of the ACTH(4-7) fragment extended with the Pro-Gly-Pro tripeptide and blocked with acetyl at the N-terminus.
- Chemical name: N-Acetyl Semax, Acetylated Semax, Ac-Semax, N-Ac-Semax
- Sequence: Ac-Met-Glu-His-Phe-Pro-Gly-Pro (single letter: Ac-MEHFPGP)
- Modification compared to Semax: acetylation of the α-amino group of the N-terminus (methionine); the heptapeptide core remains identical to Semax
- Structural origin: an analogue of the ACTH(4-7) fragment (Met-Glu-His-Phe) extended with the C-terminal tripeptide Pro-Gly-Pro; the core corresponds to native Semax
- Chemical class: modified neuroprotective/nootropic heptapeptide; melanocortin fragment of ACTH without corticotropic activity
- Supplied form: lyophilisate (powder) in a vial, 50 mg of peptide per vial, for reconstitution with bacteriostatic water; pharmaceutical grade ≥98% HPLC
Table of physicochemical characteristics
| Parameter | Value | Notes |
|---|---|---|
| Sequence | Ac-MEHFPGP | heptapeptide, N-acetylated derivative of Semax |
| CAS number (Base Semax) | 80714-61-0 | CAS for native Semax; for the N-acetylated form for verification in the batch COA |
| Molecular formula | to be confirmed by MS | acetylated form – confirmation in the batch COA |
| Molar mass | ~855 g/mol | Semax core ~813.9 Da + acetyl (+42 Da); exact value for verification in the batch COA |
| Isoelectric point | moderately acidic | the presence of glutamate and histidine residues; acetylation of the N-terminus removes the positive charge of the α-amino group |
| Form | white to off-white lyophilisate | freeze-dried powder in a vial |
| Peptide content | 50 mg/vial | before reconstitution |
| Purity | ≥98% HPLC | UV detection, per batch verification |
| Solubility | good in the water | reconstitution with bacteriostatic water |
Mechanism of action at the molecular level
N-Acetyl Semax – as a derivative of Semax – probably works through several parallel neurobiological pathways. The following mechanisms have been documented for native Semax in preclinical models; their transfer to the acetylated analogue remains under investigation. Pharmacological profile described for the Semax family in research models:
- Induction of BDNF and NGF expression in the hippocampus and cortex — the best described mechanism. Semax changes the expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the rat hippocampus: a single administration raised BDNF protein at most 1.4-fold and BDNF mRNA (exon III transcript) about threefold; the compound also affects nerve growth factor (NGF) (Dolotov et al. 2006). This is likely the core of its nootropic and neuroprotective profile – increased availability of neurotrophins promotes synaptic plasticity and neuronal survival under conditions of metabolic stress
- ACTH(4-7) analogue without corticotropic activity — Semax is derived from a fragment of ACTH, but does not contain the part of the molecule responsible for stimulating the adrenal cortex. In models, it does not stimulate cortisol secretion (no corticotropic effect), maintaining the central melanocortin profile. This distinction is important: neurotrophic and neuroprotective activity is separated from the adrenal hormonal action of parent ACTH
- Modulation of dopaminergic and serotonergic transmission — some studies indicate the effect of Semax on the expression of genes related to neurotransmission and monoamine metabolism in brain structures, which in rodent models correlates with a nootropic and neuroprotective profile (Shadrina et al. 2010). The mechanism probably involves modulation of monoamine release and influence on the expression of genes regulating dopaminergic and serotonergic transmission.
- Inhibition of enkephalinases — Semax inhibits the activity of enkephalin-degrading enzymes in serum and tissue, which increases the concentration of endogenous Met- and Leu-enkephalins and prolongs enkephalinergic signaling. This component is a likely contributor to the analgesic and anxiolytic profile observed in the models
- Neuroprotection in models of cerebral ischemia — in acute ischemia models (cerebral artery occlusion in rodents), Semax modulated apoptosis, oxidative stress and the expression of neuroinflammatory and neurotrophic response genes (Medvedeva et al. 2017). This direction was the basis for the registration of native Semax as a neuroprotector in ischemic stroke in the Russian Federation
IMPORTANT DISTINCTION
“BDNF induction and neuroprotective effects” in the context of this description means: “in in vivo rodent and cell culture models, native Semax increased BDNF/NGF expression and modified neuronal survival markers under ischemic conditions.” This does not mean a guarantee of effect in humans using the RUO reagent or a suggestion to use N-Acetyl Semax as a “memory peptide” or “neuroprotector”. Two distinctions are important for reliability here:
- N-Acetyl Semax is not native Semax. Acetylation of the N-terminus changes the lipophilicity, charge, and kinetics of the molecule; the pharmacological profile of the analogue is not simply a copy of Semax’s profile and requires separate validation. All numbers and observations quoted in this description should be read as “for the Semax family in preclinical models”, not as documented properties of the acetylated form.
- It is an ACTH analogue without corticotropic activity. Despite being derived from an ACTH fragment, Semax does not stimulate the adrenal cortex and does not increase cortisol in models. Structural origin from a stress hormone does not mean a hormonal action – the ACTH(4-7) core is responsible for a neurotropic, not adrenal profile.
Pharmacokinetics - why N-terminal acetylation matters
The difference between Semax and N-Acetyl Semax comes down to durability and lipophilicity. Native Semax has a very short half-life – on the order of minutes – because the free α-amino group of the N-terminus (methionine) is quickly cleaved by aminopeptidases. Acetylation of this group removes the enzyme’s attack point, which in research models extends the proteolytic stability of the modified molecule.
Additionally, the acetyl group increases the lipophilicity of the peptide, which may promote penetration through membranes and transport to nervous tissue. It is still a peptide with a short lifespan in the bloodstream, but capping the N-end gives the molecule actually more time to reach its target. The oral bioavailability of the peptide is virtually zero – the gastrointestinal tract degrades regulatory peptides before they can be absorbed.
In the literature, the Semax family is dominated by two routes of administration in models: parenteral and intranasal (nose-to-brain transport, partially bypassing the blood-brain barrier). The nasal route is of particular importance here: the registration of native Semax in the Russian Federation concerns the form of nasal drops. The lyophilised vial format provides the researcher with a solution of controlled concentration for any route of administration planned in the protocol. For protocols focused on the nasal route, a ready-to-use nasal spray version is available.
Applications in scientific research
N-Acetyl Semax in lyophilized format is used in research directions analogous to native Semax, with additional emphasis on characterizing the profile of the modified molecule:
- Models of neuroprotection in cerebral ischemia — middle cerebral artery occlusion (MCAO) in rodents; assessment of the effect on infarct size, neuronal apoptosis, oxidative stress and neurotrophic gene expression under acute ischemia
- BDNF, NGF and TrkB expression — transcription and protein studies in the cortex and hippocampus; comparison of the kinetics and strength of neurotrophin induction for the acetylated analogue versus native Semax
- Cognitive models — memory and learning tests (Morris water maze, passive avoidance, new object recognition), especially in conditions of cognitive impairment due to stress or hypoxia
- Neuroinflammatory models and responses to oxidative stress — assessment of the impact on the cytokine profile and oxidative stress markers in nervous tissue
- Melanocortin pharmacology of ACTH fragments — examination of the central activity of the ACTH(4-7) fragment separately from corticotropic activity; profile characterization without adrenal effect
- Pharmacokinetic characterization of modifications — comparative assessment of proteolytic stability, lipophilicity and distribution profile of the acetylated form compared to native Semax
- Monoaminergic models — influence on dopaminergic and serotonergic transmission and the expression of genes related to monoamine metabolism
Summary
N-Acetyl Semax is an N-acetylated derivative of Semax (Ac-MEHFPGP) – an analogue of the ACTH(4-7) fragment extended by the Pro-Gly-Pro tripeptide, with the N-terminal α-amino group blocked by acetyl. Supplied as a lyophilized product in a 50 mg vial for reconstitution with bacteriostatic water. It is the same compound as the nasal spray version, in a format that gives longer shelf life and freedom to choose the working concentration.
For direct comparison with the unmodified form is available Semax 50mg with a shorter half-life. N-terminal acetylation blocks aminopeptidases and increases lipophilicity, extending proteolytic stability compared to native Semax. The pharmacological profile inherited from Semax includes induction of BDNF and NGF in the hippocampus and cortex (in the rat hippocampus, BDNF protein rose at most 1.4-fold), a central melanocortin profile without corticotropic activity (does not stimulate the adrenal cortex), modulation of dopaminergic and serotonergic transmission, inhibition of enkephalinases, and neuroprotection in cerebral ischemia models – all documented for native Semax in rodent and in vitro models, with the need for separate validation for the acetylated analogue. Regulatory status – Research Use Only.
Bibliography
- Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, et al. (2006). Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. PubMed
- Shadrina M, Kolomin T, Agapova T, Agniullin Y, Shram S, Slominsky P, et al. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. PubMed
- Medvedeva EV, Dmitrieva VG, Limborska SA, Myasoedov NF, Dergunova LV (2017). Semax, an analogue of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats. PubMed
- Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. PubMed
FAQ
BDNF (brain neurotrophic factor) is a protein that supports neuron survival, synaptic plasticity and the formation of new connections. In rat models, Semax changes the expression of BDNF and its receptor TrkB, but moderately and depending on time: BDNF protein in the hippocampus rose at most 1.4-fold (Dolotov et al. 2006), while 20 minutes after administration BDNF gene expression fell in the hippocampus and rose in the frontal cortex (Shadrina et al. 2010).
This is the likely core of its nootropic and neuroprotective profile in preclinical models. However, it should be emphasized: these observations concern native Semax in animal models and in vitro, they do not guarantee the effect in humans, and the profile of the acetylated analogue requires separate confirmation.
NO. Semax is derived from a fragment of ACTH(4-7) – the part of the ACTH molecule responsible for the neurotropic profile, but not for corticotropic activity. In Semax models, it does not stimulate the adrenal cortex and does not raise cortisol – it maintains the central melanocortin profile without the hormonal effect of the parent ACTH. This deliberate separation: designing short fragments of ACTH as brain-acting neuropeptides without the adrenal effects of the full molecule was the starting point for this entire family of peptides.
Yes. The List does not name N-acetyl Semax, but as a compound with no marketing authorisation in any country it falls under class S0 (non-approved substances) and is prohibited at all times, in and out of competition. Semax’s registration in Russia does not extend to its N-acetylated derivative. Registered athletes (ADAMS) must check the current list of prohibited substances before making any decision – compound status may change in subsequent updates.
The lyophilisate before reconstitution is the most stable form – powder stored at −20°C remains stable for months because the lack of water slows down hydrolysis and degradation processes. After reconstitution with bacteriostatic water, the peptide in the aqueous phase is less stable; Store the working solution in a refrigerator at 2–8°C and use within a window of typically several weeks. The solution should not be repeatedly frozen and thawed – each cycle promotes peptide aggregation. Additionally, N-terminal methionine is susceptible to oxidation, so it is worth limiting the exposure of the solution to air and light.
Native Semax has been tested and registered as a drug – in the Russian Federation, where it has been approved in the form of nasal drops as a nootropic, and in higher concentrations as a neuroprotector in ischemic stroke (Gusev et al. 2018). However, these studies focused on native Semax, not a modified acetylated analogue.
N-Acetyl Semax, as a separate, stabilized modification, has not undergone an independent registration process in the EU, the USA or Russia – it remains a Research Use Only research reagent. This is one of the reasons why Semax data is not fully transferable to the acetylated analogue.
-
Klaudia
Polski
Product review
Bardzo szybka wysyłka. Polecam